The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial

Breast

Volumn 16, Issue 3, 2007, Pages 235-240

  Rody, A ^a   Karn, T ^a   Solbach, C ^a   Gaetje, R ^a   Munnes, M ^b   Kissler, S ^a   Ruckhaberle E ^a   Minckwitz, G v ^a   Loibl, S ^a   Holtrich, U ^a   Kaufmann, M ^a  

^a GOETHE UNIVERSITY   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Breast cancer; ErbB2; Intrinsic gene set; Molecular classification; Neoadjuvant chemotherapy

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TUMOR CLASSIFICATION;

EID: 34249050827     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.02.006     Document Type: Article

References (17)

1. Kaufmann M., Hortobagyi G.N., Goldhirsch A., Scholl S., Makris A., Valagussa P., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24 12 (2006) 1940-1949
2. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (2001) 10869-10874
3. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
4. Ahr A., Karn T., Solbach C., Seiter T., Strebhardt K., Holtrich U., et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359 (2002) 131-132
5. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 9460 (2005) 671-679
6. Perou C.M., Jeffrey S.S., van de Rijn M., Rees C.A., Eisen M.B., Ross D.T., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96 (1999) 9212-9217
7. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100 14 (2003) 8418-8423
8. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11 (2005) 5678-5685
9. Rody A., Karn T., Gatje R., Ahr A., Solbach C., Kourtis K., et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 16 1 (2007) 86-93
10. Modlich O., Prisack H.B., Munnes M., Audretsch W., and Bojar H. Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. J Transl Med 3 (2005) 32
11. Rody A., Holtrich U., Gatje R., Gehrmann M., Engels K., von Minckwitz G., et al. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of Plexin B1. Clin Cancer Res 13 4 (2007) 1210-1218
12. Eisen M.B., Spellman P.T., Brown P.O., and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95 25 (1998) 14863-14868
13. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98 (2006) 262-272
14. von Minckwitz G., Blohmer J.U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16 (2005) 56-63
15. Learn P.A., Yeh I.T., McNutt M., Chisholm G.B., Pollock B.H., Rousseau Jr. D.L., et al. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 103 (2005) 2252-2260
16. Konecny G.E., Thomssen C., Luck H.J., Untch M., Wang H.J., Kuhn W., et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 96 (2004) 1141-1151
17. Roche H.H., Penault-Llorca F.M., Sagan C., Lacroix-Triki M., Denoux Y., Verriele V., et al. Prognostic and predictive value of HER2, PR, ER, and KI67 in the PACS01 trial comparing epirubicin-based chemotherapy to sequential epirubicin followed by docetaxel. J Clin Oncol 23 16S (2005) (abstr. 605)